Welcome to our dedicated page for Jazz Pharmaceuticals news (Ticker: JAZZ), a resource for investors and traders seeking the latest updates and insights on Jazz Pharmaceuticals stock.
Jazz Pharmaceuticals plc reports developments across a global biopharma portfolio focused on rare diseases, including epilepsies, cancers and sleep disorders. Recurring updates cover commercial performance for Xywav, Epidiolex and oncology products, plus medical-conference data and real-world evidence for neuroscience and oncology programs.
Company news also includes regulatory and clinical progress for Ziihera (zanidatamab-hrii) in HER2-expressing tumors, including gastroesophageal adenocarcinoma and biliary tract cancer, along with research involving Zepzelca, Modeyso and other pipeline candidates. Updates frequently address financial results, guidance, investor conferences, collaborations and portfolio strategy.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Jazz Pharmaceuticals plc (Nasdaq: JAZZ) announced nine abstracts will be presented at the American Society of Clinical Oncology (ASCO) Annual Meeting, highlighting data on their investigational bispecific antibody, zanidatamab, particularly in treating HER2-positive biliary tract cancers (BTC). This includes pivotal Phase 2 trial results, which were chosen for oral presentation. Jazz emphasizes its role in advancing treatment standards for challenging cancers. The investor webcast scheduled for June 2, 2023, will delve into the BTC data. Other presentations feature research on Zepzelca and Vyxeos. Zanidatamab has received Breakthrough Therapy and Orphan Drug designations from the FDA for BTC and gastroesophageal adenocarcinoma.